NK1 antagonists

Details NK1 antagonists NK1 antagonists

2007-07-10

2007-07-10

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S452000

Reexamination Certificate

active

11147602

ABSTRACT:
The invention is to compounds exhibiting neurokinin inhibitory properties, pharmaceutical compositions comprising same and methods of treatment for neurokinin-mediated conditions.

REFERENCES:
patent: 6329394 (2001-12-01), Hagan et al.
patent: 0528495 (1993-02-01), None
patent: 1120723 (2001-08-01), None
Michels et al. Chemische Berichte. 1988, 121(10), 1775-83. * Indicates that the CAS Abstract and structure are attached.
Kris, M. G. Journal of Clinical Oncology, vol. 21 (22), 2003, 4077-4080.
Ramadan et al. Current Medical Research and Opinion, 17(1s), 2001, s71-s80. * Indicates only one chapter of article is provided.
Tverezovsky V.V. et al., “Synthesis of (2S,3R,4S)-3,4-Methanoproline and Analogues by Cyclopropylidnene Insertion”,Tetrahedron, Elsevier Science Publishers, Amsterdam NL, vol. 53, No. 43 Oct. 27, 1997 pp. 14773-14792.
Bonnaud, Bernard et al., “Stereoselective synthesis of cis and trans 2-substituted 1-phenyl-3-azabicyclo '3.10!hexanes”,Journal of Heterocyclic Chem., vol. 30, No. 2, p. 505.
Search Report, PCT/IB2005/001757, May 26, 2005.

Affiliated with

Also associated with

Rating

NK1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NK1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NK1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3729160